Gilead Sciences (Nasdaq: GILD) has announced that Cindy Perettie will join the firm as executive vice president of its subsidiary company Kite, overseeing the cell therapy business.
Ms Perettie will also become a member of Gilead’s senior leadership team, effective May 30, bringing with her extensive experience in oncology, which is now a major focus for the Californian biotech company.
"The cell therapy business continues to play an important role in Gilead’s ambition to become a top oncology company"Most recently, Ms Perettie was head of Roche’s (ROG: SIX) Molecular Lab Solutions, where she oversaw the polymerase chain reaction and sequencing business. Prior to that, she was chief executive at Roche-owned Foundation Medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze